{"entity":{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","aka":["Addenbrooke's Hospital","Cambridge University Hospitals","Li Ka Shing Centre"],"tldr":"The Cancer Research UK Cambridge Centre unites the university, Addenbrooke's and the CRUK Cambridge Institute; its landmark work includes METABRIC breast cancer genomics, the circulating tumour DNA methods behind Inivata, and the Cytosponge test for oesophageal cancer.","summary":"The Cancer Research UK Cambridge Centre brings together the University of Cambridge, Cambridge University Hospitals (Addenbrooke's) and the CRUK Cambridge Institute in the Li Ka Shing Centre, opened in 2007. Landmark work includes Carlos Caldas's METABRIC breast cancer genomics, Nitzan Rosenfeld's circulating tumour DNA methods that spun out Inivata, Rebecca Fitzgerald's Cytosponge test for Barrett's oesophagus and oesophageal cancer, Greg Hannon's IMAXT spatial tumour mapping, and Richard Gilbertson's paediatric brain tumour research; Cambridge chemists Shankar Balasubramanian and David Klenerman invented the Solexa sequencing chemistry now sold by Illumina. A dedicated Cambridge Cancer Research Hospital is planned on the Biomedical Campus. Patients have access to a large early-phase unit, whole-genome sequencing through the NHS Genomic Medicine Service and the Wellcome Sanger Institute's neighbouring genomics resources.","asOf":"2026-09-09","links":[{"label":"CRUK Cambridge Centre","url":"https://www.cruk.cam.ac.uk"},{"label":"Cambridge Cancer Research Hospital","url":"https://www.cambridgecancer.org.uk"}],"tags":[],"related":[],"cancers":["breast-hr-positive","esophageal","glioblastoma","ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","mrd-testing","single-cell-spatial","wes-wgs","rna-seq"],"targets":[],"drugs":[],"companies":["illumina"],"institutions":["cruk","wellcome-sanger"],"pathways":[],"terms":["ctdna","pam50"],"trials":[],"people":["jason-carroll","james-brenton","helena-earl","serena-nik-zainal","carlos-caldas","charlotte-coles","rebecca-fitzgerald","hugo-ford"],"bottlenecks":["b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.176,"lng":0.14,"institutionType":"cancer-center","website":"https://www.cruk.cam.ac.uk","university":"University of Cambridge","programs":["Breast cancer genomics (METABRIC)","Liquid biopsy and ctDNA","Early detection (Cytosponge)","Spatial tumour mapping (IMAXT)","Paediatric brain tumours"]},"route":"/institutions/cruk-cambridge-centre/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/"},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/"}],"person":[{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/"},{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/"},{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/"},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/"},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/"},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/"},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/"},{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/"},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/"},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/"},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/"}],"bottleneck":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"trial":[{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/"}],"paper":[{"id":"paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","kind":"paper","name":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","route":"/key-papers/paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013/"}]}}